Pariet

Pariet

rabeprazole

Manufacturer:

Eisai

Distributor:

Zuellig
/
HI-Eisai
Concise Prescribing Info
Contents
Rabeprazole Na
Indications/Uses
Active duodenal ulcer, active benign gastric ulcer, anastomotic ulcer, symptomatic erosive or ulcerative GERD, GERD maintenance, symptomatic GERD, Zollinger-Ellison syndrome & other pathological hypersecretory conditions. Eradication of H. pylori in patient w/ PUD in combination w/ appropriate antibacterial therapeutic regimen. Prevention of gastric & duodenal ulcer recurrences associated w/ low-dose aspirin therapy.
Dosage/Direction for Use
Adult/Elderly Active duodenal ulcer, active benign gastric ulcer & anastomotic ulcer 10 or 20 mg once daily in the morning. Erosive or ulcerative GERD 10 or 20 mg once daily for 4-8 wk. Doses of 10 or 20 mg bid may be administered for another 8 wk in reflux esophagitis patient who are not responding to the usual dose of PPIs. However, a dose of 20 mg bid should only be administered to patient w/ severe mucosa injury. GERD maintenance 10 or 20 mg once daily depending upon patient response. For the maintenance therapy when PPI treatment is ineffective, dose of 10 mg bid may be administered. Symptomatic GERD moderate to very severe 10 mg once daily for patient w/o esophagitis. If symptom control has not been achieved after 4 wk, the patient should be further investigated. Zollinger-Ellison syndrome & other pathological hypersecretory conditions Initially 60 mg daily, increase up to 100 mg once daily or 60 mg bid. Eradication of H. pylori in patient w/ PUD 10 or 20 mg + clarithromycin 500 mg & amoxicillin 1 g all bid for 7 days. Adult Prevention of gastric & duodenal ulcer recurrences associated w/ low-dose aspirin therapy 10 mg once daily. Adolescent ≥12 yr 20 mg once daily for 8 wk.
Administration
May be taken with or without food: For once daily dosing, take tab in the morning before eating. Swallow whole, do not chew/crush.
Contraindications
Hypersensitivity to rabeprazole Na & substituted benzimidazoles. Pregnancy & lactation.
Special Precautions
Exclude the possibility of malignancy prior to treatment. Monitor patient on long term treatment. Hepatic dysfunction. Hypomagnesemia. Increased risk for osteoporosis-related fractures of hips, wrist or spine & GI infection eg, C. difficile. Monitor Mg levels prior to initiation. Concomitant use w/ MTX. Subacute cutaneous lupus erythematosus (SCLE). Fundic gland polyps. Avoid driving & operating complex machinery if alertness is impaired due to somnolence. Childn <12 yr.
Adverse Reactions
Infection; insomnia; headache, dizziness; cough, pharyngitis, rhinitis; diarrhea, vomiting, nausea, abdominal pain, constipation, flatulence; nonspecific pain, back pain; asthenia, flu-like syndrome.
Drug Interactions
Significant decrease in antifungal plasma levels w/ ketoconazole, itraconazole. Potential reduction of atazanavir exposure. Delay absorption w/ high fat meal. May elevate & prolong serum levels of MTX &/or its metabolite hydroxymethotrexate.
MIMS Class
Antacids, Antireflux Agents & Antiulcerants
ATC Classification
A02BC04 - rabeprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Presentation/Packing
Form
Pariet FC tab 10 mg
Packing/Price
14's
Form
Pariet FC tab 20 mg
Packing/Price
14's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in